Indivior is bracing itself for an “expected material and rapid loss of Suboxone (buprenorphine/naloxone) film net revenue in the US” following the imminent launch of generic versions, after an appeals court denied emergency motions filed by the originator to delay a mandate that will allow Alvogen and Dr Reddy’s to launch their versions ‘at risk’ from Tuesday 19 February.
“In response, Indivior will file a petition with the Supreme Court of the US,” the originator said. It is asking the Supreme Court to stay the mandate, pending a certiorari petition that is attempting to overturn the appeals court’s decision in November last year to vacate a preliminary injunction granted against Dr Reddy’s